The data: Sixty-eight percent of US pharmacists have seen an increase in patients paying cash for GLP-1 prescriptions over the past year, according to a July Buzz Health survey of 256 pharmacists. The pattern is also routine: 61% see patients every week who pay cash for their GLP-1 medications.

Why it matters: Consumers are treating GLP-1 drugs differently than other prescriptions they fill. Sixty-three percent of pharmacists say the drug category is more likely to be paid out of pocket than any other prescription medicine.

This behavior reflects the lack of insurance coverage for weight loss drugs. Just 36% of corporate employers covered GLP-1 drugs for both weight loss and diabetes in 2026, per a June survey of 300 employer health plans by IFEBP.

But coverage gaps alone don’t explain why patients are willing to absorb the cost of GLP-1s. Low insurance coverage typically limits use of an expensive drug. But benefits like weight loss results achieved from GLP-1 use are likely driving patients’ willingness to pay: 99% of current users say they’ve experienced at least one health benefit like weight loss (86%) or reduced food noise (70%), while 97% reported at least one lifestyle benefit like feeling better in their clothing (46%) and increased confidence (27%), per a February Health survey.

Novo and Eli Lilly are building around consumers' willingness to pay for their pricy drugs with cash by using direct-to-consumer (D2C) platforms and telehealth partnerships. In mid-April, self-pay for Wegovy at retail and through NovoCares accounted for about 37% of Wegovy injectable prescriptions, per Novo Q1 filings. Lilly noted self-pay accounted for about 45% of total Zepbound prescriptions and about 55% of new Zepbound scripts, per the company’s Q2 earnings call.

Implications for pharma and telehealth marketers: As employers continue to reduce GLP-1 coverage, some patients will pay out of pocket to start or remain on treatment, expanding the customer base for D2C channels and telehealth platforms. Business Group on Health confirmed to EMARKETER that about 14% of employers have already dropped or plan to drop obesity drug coverage for US employees in 2027.

But without insurance absorbing most of the cost or access, patients spending several hundred dollars per month may approach GLP-1s more like a premium recurring purchase. Alongside clinical fit, they will weigh price clarity, clinician access, responsive service, reliable fulfillment, and ongoing support before buying again. An easy transaction may attract patients initially, but may initially attract cash-pay GLP-1 patients, but D2C pharma and telehealth platforms will retain them only by delivering a consistent experience and sustained value over time.

The shift outside insurance could also reduce the payer-claims visibility marketers use to measure patient starts, refills, and persistence. Data from D2C channels and telehealth partners will become more important for understanding use and adherence.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.